CAMIL KREIT: Open Payments
NPI 1558423780 · CLEVELAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,777 in 131 payments from 34 companies in 2025. Trend: 2023 $3,333 · 2024 $2,457 · 2025 $2,777
Food & beverage: $2,592Education: $185
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 17 | $387 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $179 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $179 |
| GlaxoSmithKline, LLC. | 9 | $177 |
| Dexcom, Inc. | 20 | $171 |
| AstraZeneca Pharmaceuticals LP | 2 | $150 |
| Axsome Therapeutics, Inc. | 7 | $145 |
| ABBVIE INC. | 5 | $123 |
| Mannkind Corporation | 3 | $107 |
| HARMONY BIOSCIENCES LLC | 1 | $100 |
Products named: Kerendia, CAPLYTA, TRELEGY ELLIPTA, Dexcom G6 Transmitter, XIFAXAN, BREZTRI, AFREZZA, INSPIRE.
Industry payments across TX — which companies pay providers there.
